Tools and resources
3 Summary of NICE recommendations
3 Summary of NICE recommendations
The NICE diagnostics guidance and this adoption support resource specifically relate to high-throughput non-invasive prenatal testing for fetal RHD genotype.
High-throughput NIPT for fetal RHD genotype is recommended as a cost-effective option to guide antenatal prophylaxis with anti‑D immunoglobulin, provided that the overall cost of testing is £24 or less.
Cost savings associated with high-throughput NIPT for fetal RHD genotype are sensitive to the unit cost of the test, additional pathway costs and implementation costs. High-throughput refers to automated instead of manual testing.
NICE also recommended further research on:
-
Data collection and analysis of the costs and resource use associated with implementing high-throughput non‑invasive prenatal testing for fetal RHD genotype to show the overall cost of testing and to inform any future update of the guidance.
-
Alternative postpartum testing strategies that do not include cord blood typing of all babies born to rhesus D (D) negative women.
This page was last updated: